You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
On the website landing page, in the "path for becoming a full Federated EGA member" diagram, where it mentions "Present use case to ELIXIR FHD Community".
Change
Feedback from nodes reviewing the materials indicates it is not clear what needs to be presented here. There have been requests for requirements and instructions for what to present. It would be useful to:
Define the requirements and/or expectations for this presentation
"Nodes are encouraged to present on topics related to: 1) national use cases for managing sensitive human omics, phenotype, and clinical data; 2) current challenges for managing sensitive human data; 3) solutions/initiatives planned or in progress to meet these challenges; and 4) how Federated EGA fits in to the node's overall goals."
Explaining in more detail and providing example presentations for this step in the "path to becoming a full FEGA member" would be beneficial to interested nodes so that they can prepare an appropriate presentation. It would help guide them in explaining their node's use case to the FHD community, and engage more efficiently with the FHD/FEGA communities. This information (and examples) is not secret, so it can definitely be shared in the onboarding materials website.
The text was updated successfully, but these errors were encountered:
Location
On the website landing page, in the "path for becoming a full Federated EGA member" diagram, where it mentions "Present use case to ELIXIR FHD Community".
Change
Feedback from nodes reviewing the materials indicates it is not clear what needs to be presented here. There have been requests for requirements and instructions for what to present. It would be useful to:
Example wording for point 1:
"Nodes are encouraged to present on topics related to: 1) national use cases for managing sensitive human omics, phenotype, and clinical data; 2) current challenges for managing sensitive human data; 3) solutions/initiatives planned or in progress to meet these challenges; and 4) how Federated EGA fits in to the node's overall goals."
Some examples for point 2:
Reason
Explaining in more detail and providing example presentations for this step in the "path to becoming a full FEGA member" would be beneficial to interested nodes so that they can prepare an appropriate presentation. It would help guide them in explaining their node's use case to the FHD community, and engage more efficiently with the FHD/FEGA communities. This information (and examples) is not secret, so it can definitely be shared in the onboarding materials website.
The text was updated successfully, but these errors were encountered: